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Background: The Adenomatous Polyposis Coli (APC) tumor suppressor is mutated or hypermethylated in up to 70 %
of sporadic breast cancers depending on subtype; however, the effects of APC mutation on tumorigenic properties
remain unexplored. Using the ApcMin/+ mouse crossed to the Polyoma middle T antigen (PyMT) transgenic model,
we identified enhanced breast tumorigenesis and alterations in genes critical in therapeutic resistance independent of
Wnt/β-catenin signaling. Apc mutation changed the tumor histopathology from solid to squamous adenocarcinomas,
resembling the highly aggressive human metaplastic breast cancer. Mechanistic studies in tumor-derived cell lines
demonstrated that focal adhesion kinase (FAK)/Src/JNK signaling regulated the enhanced proliferation downstream
of Apc mutation. Despite this mechanistic information, the role of APC in mediating breast cancer chemotherapeutic
resistance is currently unknown.
Methods: We have examined the effect of Apc loss in MMTV-PyMT mouse breast cancer cells on gene expression
changes of ATP-binding cassette transporters and immunofluorescence to determine proliferative and apoptotic
response of cells to cisplatin, doxorubicin and paclitaxel. Furthermore we determined the added effect of Src or
JNK inhibition by PP2 and SP600125, respectively, on chemotherapeutic response. We also used the Aldefluor assay to
measure the population of tumor initiating cells. Lastly, we measured the apoptotic and proliferative response to APC
knockdown in MDA-MB-157 human breast cancer cells after chemotherapeutic treatment.
Results: Cells obtained from MMTV-PyMT;ApcMin/+ tumors express increased MDR1 (multidrug resistance protein
1), which is augmented by treatment with paclitaxel or doxorubicin. Furthermore MMTV-PyMT;ApcMin/+ cells are
more resistant to cisplatin and doxorubicin-induced apoptosis, and show a larger population of ALDH positive
cells. In the human metaplastic breast cancer cell line MDA-MB-157, APC knockdown led to paclitaxel and
cisplatin resistance.
Conclusions: APC loss-of-function significantly increases resistance to cisplatin-mediated apoptosis in both
MDA-MB-157 and the PyMT derived cells. We also demonstrated that cisplatin in combination with PP2 or
SP600125 could be clinically beneficial, as inhibition of Src or JNK in an APC-mutant breast cancer patient may
alleviate the resistance induced by mutant APC.
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Breast cancer is the leading cause of cancer-related
death in non-smoking women, and the most commonly
diagnosed cancer in women in the United States [1].
Despite the tremendous amount of information about
the etiology of breast cancer, many questions remain un-
answered. Over the past 10–15 years, it has become evi-
dent that there are multiple different subtypes of breast
cancer that respond differently to chemotherapeutic and
targeted therapies [2]. Importantly, patient survival can
be predicted by a variety of factors, including subtype
and responsiveness to standard chemotherapeutic agents
([3–5] and reviewed in [6]).
The Adenomatous Polyposis Coli (by convention, the
human and mouse genes are APC and Apc, respectively,
whereas the protein from all species is APC) tumor
suppressor is mutated or silenced by hypermethylation in
up to 70 % of sporadic breast cancers depending on sub-
type ([7, 8] reviewed in [9]). APC loss-of-function most
commonly leads to activation of the Wnt/β-catenin path-
way. Multiple, less investigated roles of APC that occur
independent of Wnt activation, such as regulation of pro-
liferation, epithelial polarity, cytoskeletal organization,
microtubule stability, and DNA repair (reviewed in [9])
suggest that APC may be important in therapeutic respon-
siveness. There are several proposed mechanisms by
which chemotherapeutic resistance is conferred within
cancer including both host factors and genetic or epigen-
etic alterations [10]. ATP-binding cassette transporters
have drawn significant attention because of their ability to
regulate drug accumulation within cells. In Apc-mutant
mouse mammary glands during lactation, expression of
the ATP-binding cassette sub-family G member 2/Breast
cancer resistance protein (ABCG2/BCRP) was altered
[11], suggesting that APC may regulate therapeutic resist-
ance through mediation of ATP-binding cassette trans-
porters. In addition, tumor initiating cells (TICs) have
increased ATP-binding cassette pumps [12] and may also
be an important part of chemotherapeutic resistance.
Understanding how APC mediates sensitivity of breast
tumor cells to chemotherapy is crucial to future breast
cancer treatment, as the tumors that arise in Apc-mutant
MMTV-PyMT mice resemble human metaplastic breast
cancer, an aggressive subtype of triple-negative breast can-
cer (TNBC) with limited targeted therapies.
While breast cancer treatment varies by subtype, there
are standard therapies that are currently employed de-
pending upon subtype. The oncogenic events and signal-
ing pathways that drive these tumor subtypes are
distinct, indicating that a better understanding of their
molecular basis will provide opportunities for predicting
response to chemotherapy and the development of novel
therapeutic approaches, to ultimately improve patient out-
comes. Hormone responsive breast cancers are treatedwith specific anti-estrogens, such as tamoxifen, or mono-
clonal antibodies to HER2, such as trastuzumab. TNBC
are treated with a combination of surgery, radiation, and
systemic cytotoxic chemotherapeutic agents [13] with a
combination of taxane and anthracycline drugs being used
as the first line of defense [14]. In this study, we have
explored three chemotherapeutic agents with different
modes of action that are commonly used to treat TNBC.
Despite the differing mechanisms, paclitaxel, doxorubicin,
and cisplatin are used at various stages (neoadjuvant, adju-
vant, metastatic) to treat breast cancer [15–19], [20, 21].
Furthermore, cisplatin treatment has been shown to medi-
ate tumor response in the presence of mutant APC in
other tumor types [22].
We previously demonstrated that Apc mutation accel-
erates the MMTV-PyMT model of breast tumorigenesis
independent of Wnt/β-catenin signaling [23]. We made
the novel observation that focal adhesion kinase (FAK)/
Src/JNK signaling was enriched and required for the en-
hanced proliferation [23]. Herein we report that APC
loss-of-function in cells from the MMTV-PyMT mouse
model and metaplastic human breast cancer cell line
MDA-MB-157 results in resistance to chemotherapy-
induced apoptosis. Apc mutation in cells from the
MMTV-PyMT mouse model also results in increased
expression of MDR1 and a greater population of TICs.
Methods
Cell culture
MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cells
were isolated as previously described [23] and were grown
in RPMI 1640 media supplemented with 10 % fetal bovine
serum, 1 % penicillin/streptomycin and 1:5000 plasmocin
(Invivogen, San Diego, CA). MDA-MB-157 breast cancer
cells (ATCC, Manassas, VA) were maintained in RPMI
1640 media supplemented with 10 % fetal bovine serum, 1
% penicillin/streptomycin, 25 mM HEPES and 1:5000
plasmocin. All cells were routinely passaged using 0.25 %
trypsin/EDTA and maintained at 37 °C with 5 % CO2.
MDA-MB-157 cells were subjected to lentiviral mediated
shRNA knockdown of APC using two different MISSION
shRNA APC constructs (Sigma-Aldrich, St Louis, MO).
After transduction, cells were maintained in media con-
taining 1.5 μg/mL puromycin (Sigma-Aldrich).
Drug treatment
Cells were treated for 24 h with each chemotherapeutic
agent or solvent control: doxorubicin (MP Biomedicals,
LLC, Santa Ana, CA), paclitaxel (Sigma-Aldrich) or
cisplatin (cis-Diammineplatinum (III) dichloride, Sigma-
Aldrich). Drug concentrations for MMTV-PyMT-
derived cells were 2.5 μM paclitaxel, 16 μM cisplatin, or
500 nM doxorubicin. MDA-MB-157 cells were treated
with 0.078 μM paclitaxel, 4 μM cisplatin or 12.5 nM
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ment of the MMTV-PyMT;Apc+/+ cells from 24–72 h
showed approximately a 50 % reduction in cell popula-
tion (data not shown). For the combination treatments,
chemical inhibitors were added to the media 18 h after
chemotherapeutic agents, resulting in a 6 h treatment
with a combination of cisplatin or doxorubicin and
50 μM PP2 (Src inhibitor, Sigma-Aldrich) or 50 μM
SP600125 (JNK inhibitor, Sigma-Aldrich). For BrdU in-
corporation assays, treatment was the same as above
with the addition of 5-bromo-2’-deoxyuridine (BrdU,
10 μM, BD Pharmigen, Franklin Lakes, NJ) 8 h after
chemotherapeutic agents.Immunofluorescence
For all experiments, cells were seeded in 12 well plates
on glass coverslips for 24 h prior to treatment. For cell
proliferation via BrdU incorporation, apoptosis via
cleaved caspase 3 and APC immunofluorescence, cells
were fixed in 3.7 % formaldehyde for 15 min and then
permeabilized in 0.3 % Triton X-100 for 15 min. Im-
munofluorescence (IF) for BrdU was performed as
previously described [23]. All antibodies were diluted in
blocking buffer that consisted of 0.2 % non-fat dry milk,
2 % Bovine Serum Albumin and 0.3 % Triton X-100 in
Phosphate Buffered Saline (PBS). Cells were incubated
with primary antibodies: anti-BrdU rat monoclonal anti-
body (1:300, Abcam, Cambridge, MA), anti-cleaved cas-
pase 3 rabbit monoclonal antibody (1:400, Cell Signaling
Technology, Danvers, MA) or anti-APC (1:400, a gift from
K. Neufeld, University of Kansas) for 1 h at 37 °C.
Following washes in PBS, samples were incubated in
the appropriate secondary antibody: rhodamine conju-
gated goat anti-rat (1:100, Thermo Scientific, Rockford,
IL) or goat-anti-rabbit Alexa Fluor 488 (1:1000, Life
Technologies, Carlsbad, CA). F-actin was visualized by
co-staining with fluorescently conjugated Phalloidin
(1:200, Life Technologies) and slides were mounted
with Fluoromount G with Hoescht. The percent of
positive cells was determined for each assay with at
least 150 cells being counted per condition. Each assay
was run in triplicate and repeated three times.Table 1 Quantitative real time PCR primer sequences






Species is indicated by either an m (mouse) or h (human) before the gene nameRNA isolation and RT-PCR
MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cells
were seeded at 2.4 x105 cells/well in 6 well plates for 24 h
then treated with drugs as above for 24 h. RNA was
isolated using Tri Reagent (Molecular Research Center,
Cincinnati, OH) and cDNA synthesis was performed with
iScript from 1 μg RNA (Bio-Rad Laboratories, Hercules,
CA). Real-time RT-PCR was performed using Power SYBR
Green master mix (Applied Biosystems, Foster City, CA),
50 ng of cDNA, and 7.5 μM of each primer (primer
sequences are presented in Table 1). The amplification
program included 2 initial steps at 50 °C for 2 min and
95 °C for 10 min followed by 40 cycles of 95 °C for 15 s
and 60 °C for 1 min followed by generation of a melt curve
(CFX Connect 96 thermal cycler, Bio-Rad). Samples were
run in duplicate and 18 s rRNA was used as a reference
gene for all mouse studies. Microarray analysis on MDR1
and ABCG2 was previously described [11]. The knock-
down of APC in the MDA-MB-157 cells was verified via
quantitative real time PCR following the same protocol
with GAPDH as the reference gene.Western blots
Total protein was isolated from MMTV-PyMT tumor-
derived cells after 24 h treatment with the same chemo-
therapeutic agents as above using lysis buffer (20 mM
Tris–HCl, 150 mM NaCl, 1 % Triton-X, 0.5 % NP-40,
50, mM NaF, 1 mM Na3VO4, 5 mM Sodium pyrophos-
phate, 0.2 mM PMSF, 1x protease inhibitor cocktail
(Fisher) and 1x phosphatase inhibitor cocktail 2 (Sigma).
30 μg of protein were separated by SDS-PAGE (8 % gel),
and transferred onto Immobilon-P membrane (Milli-
pore). After transfer, membranes were blocked in 5 %
non-fat dry milk in 1 % TBS with 0.1 % Tween (TBS-T)
for 1 h at room temperature. Blots were incubated with
the primary antibody (MDR1, 1:1000 in 1 % bovine
serum albumin in TBS-T, Cell Signaling, or ABCG2,
1:100 in 5 % non-fat dry milk in TBS-T, Abcam) for 2
nights at 4 °C or β-actin (1:25000, 1 % BSA in TBS-T,
Sigma) for 1 h at room temperature. Secondary antibody
(anti-rabbit, anti-rat or anti-mouse IgG-HRP, 1:1000) was
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were developed with Clarity ECL regent (Bio-rad) and a
ChemiDoc MP Imaging System (Bio-rad). Densitometry
quantification was performed using ImageJ software
(NIH). Blots are representative of three runs.
ALDEFLUOR assays
Aldehyde dehydrogenase (ALDH) enzyme activity was
determined using the ALDEFLUOR™ Kit (Stem Cell
Technologies, Vancouver, British Columbia, Canada)
according to the manufacturer’s protocol. Briefly 2.0x105
MMTV-PyMT;Apc+/+ or MMTV-PyMT;ApcMin/+ cells
were suspended in Aldefluor™ assay buffer containing
ALDH substrate (Bodipy-Aminoacetaldehyde) which
served as the “test” sample. An identical sample served as
the “control” containing the ALDH substrate and diethyla-
minobenzaldehyde (DEAB), a specific ALDH1 enzyme in-
hibitor. Both the test and control samples were incubated
for 60 min at 37 °C. The fluorescent ALDH-expressing
cells were detected in the green fluorescence channel
(515–535 nm) of a Cytotomics FC 500 (Beckman Coulter,
Brea, CA) flow cytometer. Data were analyzed using
FlowJo Flow Cytometry Data Analysis Software (Tree Star,
Ashland, OR). The percent shift between gated events in
the test versus control samples was calculated; a greater
shift indicates a greater number of ALDH positive cells in
a given sample.
Statistical analysis
Student’s t-tests were used for all analyses except the
combination treatments where a two-way ANOVA with
Bonferroni post-hoc test was used. A p-value < 0.05 was
considered significant.
Results
One major mechanism of chemotherapeutic resistance is
the presence of ATP-dependent efflux pumps to regulate
the rate at which chemotherapeutic drugs are effluxed
out of a cell and control the amount of drug remaining
within the cell [10]. Through microarray analysis, our
laboratory previously demonstrated that ABCG2 expres-
sion was down-regulated in Apc-mutant mouse mam-
mary glands during lactation [11]; however, MDR1
expression was significantly increased (Fig. 1a). MDR1 is
one of the most common efflux pumps that confers che-
motherapeutic resistance and has been shown to regu-
late efflux of paclitaxel and doxorubicin [12]. Consistent
with the developmental studies (Fig. 1a), cells isolated
from MMTV-PyMT;ApcMin/+ tumors showed a signifi-
cant increase of MDR1 expression compared to control
MMTV-PyMT;Apc+/+ cells (Fig. 1b, Additional file 1).
Treatment with paclitaxel and doxorubicin, but not cis-
platin, further enhanced expression of MDR1 in
MMTV-PyMT;ApcMin/+ cells (Fig. 1b, Additional file 1).Doxorubicin treatment also enhanced MDR1 protein
expression in MMTV-PyMT;ApcMin/+ cells (Fig. 1d and e,
Additional file 1). We observed no changes in the expres-
sion of ABCG2 after treatment with chemotherapeutic
agents (Fig. 1c, Additional file 1). However MMTV-
PyMT;Apc+/+ have a greater expression of ABCG2 protein
compared to MMTV-PyMT;ApcMin/+ cells (Fig. 1d and f,
Additional file 1).
Given the increase in MDR1 expression, we hypothe-
sized that Apc mutation may therefore confer chemother-
apeutic resistance. To test this hypothesis, we measured
cell proliferation and apoptosis after a 24-hour treatment
with cisplatin, paclitaxel or doxorubicin. BrdU incorpor-
ation demonstrated that while paclitaxel treatment did not
alter cell proliferation, the impact of cisplatin and doxo-
rubicin on proliferation was modestly enhanced in
MMTV-PyMT;ApcMin/+ cells (Fig. 2a, Additional file 1).
Given the mechanisms of action of chemotherapeutic
agents, and the lack of a strong proliferative effect, we
used cleaved caspase 3 IF to determine whether Apcmuta-
tion decreased the rate of apoptosis after chemotherapeutic
treatment. As expected, no difference was observed in the
percent of apoptosis in control (vehicle-treated) MMTV-
PyMT;ApcMin/+ versus MMTV-PyMT;Apc+/+ cells (Fig. 2b
and c, Additional file 1). However, MMTV-PyMT;ApcMin/+
cells had decreased cisplatin- or doxorubicin-induced
apoptosis compared to MMTV-PyMT;Apc+/+ (Fig. 2b and
c, Additional file 1). No difference in paclitaxel-induced
apoptosis was observed in the two cell lines.
We previously demonstrated that mutant Apc in the
MMTV-PyMT mouse model increased proliferation
and expression of pFAK, pSrc and pJNK, and that inhib-
ition of Src or JNK diminishes the APC-mediated cell
proliferation [23]. Given the effect of Apc status on
cisplatin- and doxorubicin-mediated apoptosis (Fig. 2b,
Additional file 1) and to understand whether the Src/
JNK signaling pathway could impact chemotherapeutic
resistance, we measured apoptosis in cells treated with a
combination regimen. Cells were treated with either
cisplatin or doxorubicin in combination with either an
inhibitor to Src (PP2) or JNK (SP600125). The addition
of PP2 or SP600125 to cisplatin significantly increased
apoptosis compared to cisplatin alone in MMTV-
PyMT;ApcMin/+cells (Fig. 3a and c, Additional file 1).
Therefore the cisplatin-mediated apoptosis becomes
equivalent in the two cell lines with the inhibition or Src
or JNK. It is also evident that cisplatin and doxorubicin
have differing modes of action because the doxorubicin-
mediated apoptosis in the MMTV-PyMT;ApcMin/+ cells
was not affected by the addition of PP2 or SP600125
(Fig. 3b, Additional file 1).
TICs have been shown to have higher levels of ABC
transporters or efflux pumps compared to normal differen-
tiated cells [12], and impact chemotherapeutic resistance.
Fig. 1 (See legend on next page.)
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Fig. 1 Gene expression of ATP-dependent binding cassette transporters. a Microarray analysis of mammary glands from ApcMin/+ and Apc+/+
mice at d16 of lactation show a decrease in ABCG2 and increase in MDR1 expression due to Apc mutation. b MDR1 gene expression in cells
from MMTV-PyMT;ApcMin/+ and MMTV-PyMT;Apc+/+ mice after 24 h treatment with either solvent control, paclitaxel, cisplatin or doxorubicin.
MDR1 expression was significantly increased in cells from MMTV-PyMT;ApcMin/+ mice after treatment with paclitaxel and doxorubicin but not
cisplatin. c ABCG2 gene expression in cells from MMTV-PyMT;ApcMin/+ and MMTV-PyMT;Apc+/+ mice after treatment for 24 h with either
solvent control, paclitaxel, cisplatin or doxorubicin. ABCG2 expression was not different between MMTV-PyMT;ApcMin/+ and MMTV-PyMT;Apc+/+
cells and chemotherapy treatment had no effect on ABCG2 expression. d Representative western blots for MDR1 and ABCG2 in cells from
MMTV-PyMT;ApcMin/+ and MMTV-PyMT;Apc+/+ mice after treatment for 24 h with either solvent control, paclitaxel, cisplatin or doxorubicin. e
Quantification of MDR1 western blots shows that MMTV-PyMT;ApcMin/+ cells have enhanced MDR1 expression when treated with doxorubicin.
f Quantification of ABCG2 western blots shows that MMTV-PyMT;Apc+/+ cells have elevated ABCG2 protein expression compared to MMTV-PyMT;ApcMin/+
cells. Results in B, C, E and F are shown as the means ± SEM from 3 independent experiments; *P < 0.05 when comparing MMTV-PyMT;ApcMin/+ to
MMTV-PyMT;Apc+/+ cells and #P < 0.05 when comparing MMTV-PyMT;ApcMin/+ cells treated with solvent control or chemotherapy agent.
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and therefore cause tumor recurrence are often TICs. A
common mechanism to measure TICs is through the use
of the ALDEFLUOR assay using FACS, where 23 out of 33
human breast cancer cell lines were found to be positive
[24]. Therefore we used the ALDEFLUOR assay to deter-
mine the population of TICs. Cells were incubated with
ALDH substrate in the presence (control) or absence (test)
of the ALDH enzyme inhibitor, diethylaminobenzaldehyde
(DEAB). The gated (ALDH−) population in the control
condition was unchanged in the Apc-mutant versus wild-
type cells (Fig. 4a, 97.7 % compared to 95.5 %). However,
in the absence of the ALDH inhibitor, the gated population
changed from 77.8 % in the MMTV-PyMT;Apc+/+cells to a
mere 20.3 % in the MMTV-PyMT;ApcMin/+ cells, indicat-
ing that Apc mutation increases the TIC population (Fig. 4)
a and b.
To translate our results from mouse cell lines to a hu-
man cell line, we turned to MDA-MB-157 cells, which
are a triple negative breast cancer cell line derived from
a pleural effusion from a metaplastic human breast can-
cer [25]. This specific cell line was chosen because of the
metaplastic-like tumors that developed in the MMTV-
PyMT;ApcMin/+ model [23]. As MDA-MB-157 cells have
wild-type APC [26–27] we used lentiviral mediated
shRNA to knockdown APC and observed a 60 % de-
crease in APC gene expression (Fig. 5a). Using immuno-
fluorescence we observed that APC knockdown cells
had decreased APC protein expression at the membrane
and nucleus (Fig. 5b). Baseline cell proliferation was not
changed in the APC knockdown cells (data not shown).
Treatment with cisplatin, doxorubicin or paclitaxel did
not impact proliferation in the APC knockdown lines
compared to the parent line (Fig. 5c, Additional file 1),
similar to the effects in the PyMT-derived model (Fig. 2).
APC knockdown MDA-MB-157 cells exhibited de-
creased apoptosis after treatment with paclitaxel or cis-
platin (Fig. 5d and e, Additional file 1). While paclitaxel
response was not previously shown to be dependent on
APC status (Fig. 2b), the impact of APC on cisplatin re-
sponse (Fig. 2b, and 5d) is consistent between the twomodel systems. In contrast to the results in the PyMT
model system (Figs. 2b) doxorubicin-mediated apoptosis
was not altered by APC-status in the MDA-MB-157 cell
system (Fig. 5d).
Discussion
The recurrence of breast cancer, which accounts for 90 %
of breast cancer-related deaths [13], is often accompanied
by chemotherapeutic resistance [28]. Therefore, it is crit-
ical to investigate the biological markers involved with this
process. Many mechanisms have been attributed to the
development of chemotherapeutic resistance; however,
one of the most well-known is the multidrug resistance
theory. The expression of efflux pumps that regulate the
rate in which drugs can remain in cells and increased
expression or activity of these pumps leads to increased
chemotherapeutic resistance. TICs or cancer stem cells
express high levels of ABC transporters [12, 29] and are
more resistant to chemotherapeutic agents than other
tumor cells [30]. Our results in the mouse cell model sup-
port this claim because MMTV-PyMT;ApcMin/+ cells have
increased TICs and higher levels of MDR1 expression. We
previously reported that mutant Apc in the MMTV-PyMT
model increased FAK activation [23]. FAK deletion has
been shown to decrease the number of TICs present in
both breast cancer [31–33] and skin cancer [34]. There-
fore, the regulation of FAK by APC may be contributing
to the change in the number of TICs through blocking the
process of self-renewal.
ALDH-positive cells are more metastatic than ALDH-
negative cells [24] and increased ALDH activity leads to
poor clinical prognosis [35]. Cisplatin and paclitaxel re-
sistant cell lines have increased ALDH expression com-
pared to parent cells [36, 37]. ALDH positive cells have
increased expression of STAT3 (signal transducer and
activator of transcription 3) [38] which makes STAT3 an
ideal target for decreasing the TIC population in
MMTV-PyMT;ApcMin/+ cells. In addition to commer-
cially available STAT3 inhibitors [39], miR-337-3p, a ma-
ture sequence of miR-337, can also inhibit STAT3,
sensitizing lung cancer cells to paclitaxel treatment [40].
Fig. 2 Cell proliferation and apoptosis in MMTV-PyMT;ApcMin/+ and MMTV-PyMT;Apc+/+ cells after treatment with paclitaxel, cisplatin and doxorubicin. a Cell
proliferation as measured by BrdU incorporation after chemotherapuetic treatment. MMTV-PyMT;ApcMin/+ cells showed a modest decrease in proliferation
after treatment with cisplatin and doxorubicin compared to MMTV-PyMT;Apc+/+ cells. b Apoptosis as measured by cleaved caspase 3 immunofluorescence
(IF). The percentage of apoptosis was lower in cisplatin and doxorubicin treated MMTV-PyMT;ApcMin/+ compared to MMTV-PyMT;Apc+/+ cells while paclitaxel
treatment did not affect apoptosis levels. c Representative images of cleaved caspase 3 (CC3) IF. The scale bar is equal to 200 microns. White arrows are
representative cleaved caspase 3 positive cells. Data are shown as the means ± SEM from 3 independent experiments; *P < 0.05
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breast cancers [41] and non-inflammatory breast cancer
samples from Tunisian women [42]. Another important
factor is miR-135a, which binds to the APC gene [43, 44],
and inhibits STAT3-induced pro survival gene expression
and induces apoptosis in gastric cancer and lymphoma
[45]. Future work will determine the impact of treatment
with FAK and STAT3 inhibitors on the TIC population in
MMTV-PyMT;ApcMin/+ cells as a means to regulate che-
motherapeutic resistance.The MMTV-PyMT;ApcMin/+ cells exhibited increased
MDR1 expression, which would be expected to increase
chemotherapeutic resistance. MDR1 expression in
MMTV-PyMT;ApcMin/+ cells was augmented by doxo-
rubicin and paclitaxel but not with cisplatin (Fig. 1),
which is supported by currently published data that
MDR1 effluxes both doxorubicin and paclitaxel but not
cisplatin [12]. While studies have identified APC as a
driver of multidrug resistance through the Wnt/β-ca-
tenin signaling in colorectal cancer [46–49], we have not
Fig. 3 Apoptosis in MMTV-PyMT;ApcMin/+ and MMTV-PyMT;Apc+/+ cells treated with chemotherapeutic drugs and targeted inhibitors. a Apoptosis was
measured by cleaved caspase 3 IF in the presence of cisplatin. Treatment with cisplatin and either PP2 or SP600125 significantly increases apoptosis compared
to cisplatin alone in MMTV-PyMT;ApcMin/+cells. No effect was observed with the addition of PP2 or SP600125 in the MMTV-PyMT;Apc+/+cells. b Apoptosis was
measured by cleaved caspase 3 IF with doxorubicin treatments. c Representative cleaved caspase 3 IF images of cells treated with cisplatin and the targeted
inhibitor. The scale bar is equal to 200 microns and arrows are used to depict specific cleaved caspase 3 (CC 3) positive cells in each image. Data are shown
as the means ± SEM from 3 independent experiments; *P < 0.05 when comparing MMTV-PyMT;ApcMin/+ to MMTV-PyMT;Apc+/+ cells and ** P < 0.05 when
comparing the combination treatment versus a single agent (cisplatin or doxorubicin)
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ously reported the effects of Apc mutation in the
MMTV-PyMT mouse model to be independent of Wnt/
β-catenin signaling [23]. Microarray analysis of the
NCI60 cell lines showed that there is an inverse relation-
ship between drug resistance and MDR1 expression for
18 different compounds including doxorubicin and pac-
litaxel [50]. Doxorubicin-resistant MDA-MB-435 or
MCF-7 cells [51–53] have increased MDR1, suggesting
elevated MDR1 may be the mechanism by which APCmutation causes doxorubicin-resistance. Increased MDR1
will enhance doxorubicin efflux out of cells and thus de-
crease the intracellular drug accumulation. In addition,
doxorubicin has been shown to increase MDR1 in B-cell
lymphoma cells through activation of the Mitogen
Activated Protein Kinase/Extracellular-signal-Regulated
Kinases (MAPK/ERK) signaling pathway [54]. Conversely
antibody-based microarray analysis determined that
doxorubicin-resistant MDA-MB-231 have decreased pro-
tein expression of p-ERK1, cyclin B1 and cyclin D2 [55].
Fig. 4 MMTV-PyMT;ApcMin/+ cells have higher aldehyde dehydrogenase (ALDH) enzyme activity than MMTV-PyMT;Apc+/+ cells. ALDH activity was measured
using an Aldefluor™ Kit. For each cell line a Control (+DEAB) and test (−DEAB) sample were run. a Representative FACS analysis of ALDH activity in MMTV-
PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cells using the Aldefluor™ assay. ALDH activity is increased in MMTV-PyMT;ApcMin/+ cells. b The population of cells that
shifted outside of the control population was calculated for each test sample, indicating ALDH activity. MMTV-PyMT;ApcMin/+cells show a larger percentage
of cells shifted outside of the control range than MMTV-PyMT;Apc+/+cells. Data are shown as the means ± SEM from 3 independent experiments; *P < 0.05
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Fig. 5 APC knockdown in MDA-MB-157 cells impacts response to paclitaxel and cisplatin. a Quantitative RT-PCR in MDA-MB-157 cells and shAPC con-
structs shows decreased level of APC in cells infected with the shAPC constructs. b Representative APC immunofluorescence images showing that APC
knockdown cells have less APC protein compared to the MDA-MB-157 parent line. c Cell proliferation as measured by BrdU incorporation did not differ
between the three cell lines after treatment with cisplatin, doxorubicin or paclitaxel. d Apoptosis as measured by cleaved caspase 3 IF. The percentage of
apoptosis was lower in paclitaxel treated shAPC 1 and cisplatin treated shAPC 2 cells compared to MDA-MB-157 control cells. Doxorubicin treatment had
no effect on rates of apoptosis. e Representative images of CC3 IF. Although there are a similar number of positive cells in many of the images, there are
fewer total cells in those images representing treatments with a higher percent of apoptosis. The scale bar is equal to 100 microns (E) and 20 microns (B).
Data are shown as the means ± SEM from 3 independent experiments; *P < 0.05
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ing basal and drug induced MDR1 expression in breast
cancer. To link MDR1 expression to chemotherapeutic
responsiveness and decreased apoptosis, future work will
block expression of MDR1 using PSC833 [56], which has
been previously used in breast cancer to inhibit MDR1
expression (reviewed by [57]).
Further studies are needed to delineate the mechanism
responsible for the differences seen between doxorubicin
and cisplatin, and the differences between the PyMT-
derived cells and the MDA-MB-157 human breast cancer
cell line. DNA damage repair mechanisms may also be
affected by Apc mutation as cisplatin directly and doxo-
rubicin indirectly cause DNA damage [58]. Mutation in
Apc is known to increase a cell’s ability to repair mutated
DNA [59, 60], and its interaction with DNA polymerase β
(Pol-β) and flap endonuclease 1 (Fen-1) inhibits single nu-
cleotide and long-patch excision repair [59, 61, 62]. There-
fore we may expect that MMTV-PyMT;Apc+/+ cells might
undergo apoptosis while MMTV-PyMT;ApcMin/+ cells
would survive and these effects may vary by the direct
(cisplatin) versus indirect (doxorubicin) effects on DNA
damage.
Given that both models tested show that APC medi-
ates response to cisplatin, future studies will elaborate
on cisplatin resistance. Cisplatin resistance can include
multiple pathways: increased drug efflux, evasion of
apoptotic pathways, bypass of the replication checkpoint,
increased cell proliferation and increased DNA damage
repair [63], and thus it might be harder to delineate a
specific mechanism. However, previous studies have
demonstrated that APC mediates sensitivity to cisplatin
in multiple tumor types including breast cancer [22].
We propose that one potential target may be drug efflux
by, and expression of, ATP-binding cassette sub-family
C member 2 (ABCC2) because it effluxes cisplatin [12]
and can be found in breast cancer cells [12, 64]. This
mechanism will need to be determined as we observed
the most promising effect with combination treatment
of cisplatin with Src or JNK inhibition. This is not the
first report of drug resistance occurring via different
mechanisms. In doxorubicin- and mitoxantrone- resist-
ant MCF-7 breast cancer cells, both drugs led to de-
creased drug accumulation and enhanced drug effluxbut only doxorubicin resistant cells had an increase in
permeability factor glycoprotein-p170 (Pgp) expression
[65]. Through microarray analysis both MCF-7 breast
cancer cells and two different leukemia cell lines not
only have increased expression of the ABC transporter
reported to be overexpressed for each in the literature
but also in several other efflux pumps [66]. This finding
implies that it may be important to study multiple trans-
porters in the case of chemotherapeutic resistance. There
is redundancy in expression of different ABC transporters
within resistant cells that may increase the difficulty in
delineating which ABC transporters are explicitly driving
chemotherapeutic resistance [50, 58].
The cisplatin-mediated changes in combination with
PP2 and SP600125 corroborate results by others that dem-
onstrate a synergistic effect between Src inhibition and
cisplatin in breast and non-small lung cancer cell lines
[67, 68]. The importance of Src in chemotherapeutic re-
sistance was also demonstrated in human gallbladder
adenocarcinoma cells where Src increased chemothera-
peutic resistance by increasing the repair of cisplatin-DNA
interstrand cross-links [69]. In addition to our data show-
ing an enhanced response of Apc-mutant breast cancer
cells to SP600125, previous studies have indicated a role of
APC in mediating sensitivity to the JNK inhibitor VIII
[22]. JNK has been shown to be important in cisplatin-
mediated apoptosis in cell culture models for sarcoma
[70] and lung cancer [71–73]. Moreover we saw similar
cisplatin resistance in our human breast cancer cell line
model, suggesting a global mechanism of resistance. These
data imply that treatment of a patient with an APC-mu-
tant breast cancer with Src or JNK inhibitors in combin-
ation with cisplatin would result in restored sensitivity to
cisplatin.
Paclitaxel affects microtubule binding ([74, 75] and
reviewed in [9]) and APC is required for the ability of
EB1 to promote microtubule polymerization [76] by
cooperating with EB1 to cap the plus ends of microtu-
bules, thus preventing exchange of tubulin subunits [77].
APC deficiency in models of intestinal cancer strongly
suppresses tumorigenesis due to a defect in microtubule
stabilization [78]. Although Apc mutation in the PyMT-
model did not result in paclitaxel resistance, we ob-
served changes in MDR1 expression after paclitaxel
VanKlompenberg et al. BMC Cancer  (2015) 15:457 Page 12 of 14treatment. Consistent with our data in MMTV-
PyMT;ApcMin/+cells (Fig. 1), paclitaxel treatment upregu-
lates MDR1 expression in MCF-7 breast cancer cells
[79]. The pathway responsible for the paclitaxel-
mediated MDR1 overexpression in MCF-7 breast cancer
cells is via early growth response gene-1 (egr-1) [79].
While MDR1 expression was increased in the presence
of paclitaxel treatment, no change in apoptosis was
observed in Apc-mutant cells. Despite this, we have
shown here that APC status in the MDA-MB-157 cells
dictates resistance to paclitaxel. One potential reason for
this discrepancy in the two cell lines may be related to
the finding that in some cases the effects of paclitaxel
has been linked to changes in autophagy and not apop-
tosis [80]. Inherent differences in gene expression pro-
files in the two model systems tested may also be
responsible for the differences in chemo-responsiveness,
and will be further investigated in the laboratory. Re-
cently work has also shown that miR-135a contributes
to paclitaxel resistance in vitro in cell culture models for
non-small cell lung cancer, breast cancer and ovarian
cancer while in vivo work with a non-small cell lung
cancer model demonstrated a similar response [44]. This
work is important to our study because miR-135a down-
regulates APC gene expression [43, 44] and thus may be
responsible affecting chemotherapeutic resistance in our
model systems.
Conclusions
In this body of work we have shown that Apc mutation in
the MMTV-PyMT mouse model leads to increased ex-
pression of MDR1, which is enhanced after treatment with
doxorubicin and paclitaxel. Apc mutation also decreases
cisplatin- or doxorubicin-mediated apoptosis. Treatment
of Apc-mutant cells with a combination of cisplatin and
Src or JNK inhibitors restores apoptosis to a level similar
to the control cells. This is a significant finding that has
the potential to eliminate chemotherapeutic resistance in
APC-mutant breast cancers. Results from the human
metaplastic breast cancer cell line MDA-MB-157 showed
APC knockdown resulted in resistance to apoptosis in
both cisplatin and paclitaxel. Taken together these results
demonstrate that APC loss-of-function significantly im-
pacts chemotherapeutic resistance.
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